Announcements Trials

Browse Landscape

Phase

Phase 4 2 Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Gynecologic 1 Classical hematology 1

Conditions

Anemia, Iron-Deficiency 1

Interventions

Epoetin Alfa 27 Darbepoetin alfa 13 Cytarabine 9 Dalteparin 8 Rivaroxaban 7 Daunorubicin 7 apixaban 6 Etoposide 6 Methotrexate 5 Idarubicin 5 Heparin, Low-Molecular-Weight 5 Cyclophosphamide 5 emicizumab 4 Tinzaparin 4 Thioguanine 4 Mitoxantrone 4 Granulocyte Colony-Stimulating Factor 4 Filgrastim 4 Enoxaparin 4 pegfilgrastim 3 hetrombopag 3 epoetin beta 3 Saline Solution 3 Radiotherapy 3 Hydrocortisone 3 Erythropoietin 3 Dexamethasone 3 Aspirin 3 Asparaginase 3 telapristone acetate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × iron isomaltoside 1000 × Classical hematology × Clear all

NCT05467319 2022-07-20

FORGE

Alberta Health Services, Calgary

Phase 3 Unknown

Classical hematology

Anemia, Iron-Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon ⚡